Boehringer Ingelheim Press Releases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Leading Patient and Professional Advocacy Organizations Endorse the 4WARD Coalition Resource to Advance Anticoagulation Care
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 3, 2016 Category: Research Source Type: news

Boehringer Ingelheim returns development and commercial rights of olmutinib to Hanmi Pharmaceutical
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 29, 2016 Category: Research Source Type: news

Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 28, 2016 Category: Research Source Type: news

Boehringer Ingelheim boosts immune-oncology pipeline through collaboration with ViraTherapeutics
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 27, 2016 Category: Research Source Type: news

Boehringer Ingelheim Named to the 2016 Working Mother 100 Best Companies List
This is the fifth consecutive year the company has earned this prestigious honor (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 26, 2016 Category: Research Source Type: news

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 8, 2016 Category: Research Source Type: news

New analysis showed dose adjustment of Gilotrif ® (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 7, 2016 Category: Research Source Type: news

New Long-Term Data Demonstrates Continued Safety and Beneficial Effect of Ofev ® (Nintedanib) for Patients with IPF
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 6, 2016 Category: Research Source Type: news

Tiotropium RESPIMAT ® Improved Lung Function with Safety Comparable to Placebo in Children with Asthma
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 5, 2016 Category: Research Source Type: news

New Data: STIOLTO ® RESPIMAT® (tiotropium bromide+olodaterol) Inhalation Spray Significantly Improved Exercise Capacity in People with COPD
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 4, 2016 Category: Research Source Type: news

Simple Blood Test Combined with Exacerbation History May Help to Identify When to Add ICS to COPD Treatment
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 4, 2016 Category: Research Source Type: news

Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE ® immuno-oncology drug for multiple myeloma
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - August 31, 2016 Category: Research Source Type: news

Qualcomm and Boehringer Ingelheim Pharmaceuticals collaborate to add new digital technology to RESPIMAT ® inhaler
-- Two industry leaders combine strengths in health care and technology to aim to improve chronic obstructive pulmonary disease (COPD) care – (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - August 29, 2016 Category: Research Source Type: news

ESC Congress 2016 Late Breaking Science Registry: Latest Data on Pradaxa (dabigatran etexilate mesylate) Safety and Effectiveness Profile Show Low Rates of Bleeding and Stroke in NVAF Patients in Routine Clinical Care
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - August 28, 2016 Category: Research Source Type: news

Boehringer Ingelheim and Duke Clinical Research Institute Expand Collaboration to Create Largest Patient Registry for Idiopathic Pulmonary Fibrosis (IPF)
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - August 24, 2016 Category: Research Source Type: news